These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36274640)

  • 21. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A
    Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
    Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
    Expert Rev Vaccines; 2022 Dec; 21(12):1873-1881. PubMed ID: 35792752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older.
    Chen Y; Zhang X; Gong L; Liang Z; Hu X; Xing B; Liao Y; Yuan L; Chen G; Lv H
    Expert Rev Vaccines; 2023; 22(1):1079-1090. PubMed ID: 37877219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.
    Zamani B; Moradi Hasan-Abad A; Piroozmand A; Dehghani M; Arfaatabar M; Motedayyen H
    Immun Inflamm Dis; 2023 May; 11(5):e858. PubMed ID: 37249277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
    Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
    Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
    Sharif H; Ghani H; Ahmad L; Bagol S; Wong J; Tan CW; Zhu F; Wang LF; Naing L; Cunningham AC
    Vaccine; 2023 Nov; 41(47):6910-6913. PubMed ID: 37880070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers.
    Matula Z; Bekő G; Király V; Gönczi M; Zóka A; Baráth A; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38276662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.
    Liu HH; Xie Y; Yang BP; Wen HY; Yang PH; Lu JE; Liu Y; Chen X; Qu MM; Zhang Y; Hong WG; Li YG; Fu J; Wang FS
    Signal Transduct Target Ther; 2024 May; 9(1):129. PubMed ID: 38740763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization.
    Cheng ZJ; Huang H; Zheng P; Xue M; Ma J; Zhan Z; Gan H; Zeng Y; Lin R; Li S; Zhong R; Li S; Wang H; Sun B
    Allergy; 2022 Aug; 77(8):2404-2414. PubMed ID: 35255171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection.
    Jeewandara C; Aberathna IS; Dayarathna S; Nimasha T; Ranasinghe T; Jayamali J; Kamaladasa A; Karunanada M; Perera L; Ogg GS; Malavige GN
    PLoS One; 2022; 17(10):e0274845. PubMed ID: 36227884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report.
    Lijeskić O; Klun I; Stamenov Djaković M; Gligorić N; Štajner T; Srbljanović J; Djurković-Djaković O
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China.
    Zeng G; Xu L; Feng S; Tang J; Wang X; Li G; Gan Y; Zheng C; Zhao J; Yang Z
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.
    Wang Q; Ning J; Chen Y; Li B; Shi L; He T; Zhang F; Chen X; Zhai A; Wu C
    Front Microbiol; 2022; 13():1008420. PubMed ID: 36406456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing.
    Tong R; Luo L; Zhao Y; Sun M; Li R; Zhong J; Chen Y; Hu L; Li Z; Shi J; Lyu Y; Hu L; Guo X; Liu Q; Shuang T; Zhang C; Yuan A; Sun L; Zhang Z; Qian K; Chen L; Lin W; Chen AF; Wang F; Pu J
    Emerg Microbes Infect; 2023 Dec; 12(1):e2187245. PubMed ID: 36987861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
    Al Kaabi N; Oulhaj A; Al Hosani FI; Al Mazrouei S; Najim O; Hussein SE; Abdalla JS; Fasihuddin MS; Hassan AA; Elghazali G; Al Rumaithi A; Al Azazi J; Weber S; Beiram R; Parekh KA; Sheek-Hussein M; Yang Y; Xiaoming Y; Quliang J; Eltantawy I; Mahmoud S; Koshy A; Xiao P; Ganesan S; Elamin W; Zaher W
    Sci Rep; 2022 Jan; 12(1):490. PubMed ID: 35017530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.
    Rákóczi É; Magócs G; Kovács S; Nagy B; Szűcs G; Szekanecz Z
    Diagnostics (Basel); 2023 Feb; 13(3):. PubMed ID: 36766663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.